Skip to content
ppharmaranks
Menu
Class IIOngoing

4.2% Sodium Bicarbonate Injection recall

FDA recall D-0620-2025 · initiated Jul 30, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Sep 17, 2025How we research

Exela Pharma Sciences LLC recalled 4.2% Sodium Bicarbonate Injection in Jul 2025 — an FDA Class II recall (D-0620-2025) because Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot # 10004077, Exp. 02/28/2026

Quantity recalled: N/A

Details

Product
4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA, NDC 51754-5012-1 (vial); 51754-5012-4 (carton)
Recalling company
Exela Pharma Sciences LLC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jul 30, 2025
FDA report date
Sep 17, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was 4.2% Sodium Bicarbonate Injection recalled?
Exela Pharma Sciences LLC recalled 4.2% Sodium Bicarbonate Injection in Jul 2025 — an FDA Class II recall (D-0620-2025) because Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested. May cause temporary or medically reversible harm; low probability of serious harm.
Why was 4.2% Sodium Bicarbonate Injection recalled?
Per the FDA enforcement record, the reason for recall D-0620-2025 was: Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.
Is a recalled 4.2% Sodium Bicarbonate Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of 4.2% Sodium Bicarbonate Injection are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot # 10004077, Exp. 02/28/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0620-2025.

Source: openFDA Drug Enforcement record D-0620-2025

← All drug recalls